Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

[1] Karran E(2011)The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics Nat Rev Drug Discov 10 698-712

[2] Mercken M(2002)The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics Science 297 353-356

[3] De Strooper B(1991)The molecular pathology of Alzheimer’s disease Neuron 6 487-498

[4] Hardy J(2012)An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ J Neurosci 32 9677-9689

[5] Selkoe DJ(2016)Structure of crenezumab complex with Aβ shows loss of β-hairpin Sci Rep 6 39374-566

[6] Selkoe DJ(2015)Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region J Nucl Med 56 560-459

[7] Adolfsson O(2015)Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction NeuroImage 108 450-574

[8] Pihlgren M(2015)Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios J Nucl Med 56 567-e1897

[9] Toni N(2018)ABBY: a phase 2 randomized trial of crenezumab in mild-to-moderate Alzheimer’s disease Neurology 90 e1889-198

[10] Varisco Y(1975)“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 189-1095

[1] Karran E(2011)The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics Nat Rev Drug Discov 10 698-712

[2] Mercken M(2002)The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics Science 297 353-356

[3] De Strooper B(1991)The molecular pathology of Alzheimer’s disease Neuron 6 487-498

[4] Hardy J(2012)An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ J Neurosci 32 9677-9689

[5] Selkoe DJ(2016)Structure of crenezumab complex with Aβ shows loss of β-hairpin Sci Rep 6 39374-566

[6] Selkoe DJ(2015)Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region J Nucl Med 56 560-459

[7] Adolfsson O(2015)Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction NeuroImage 108 450-574

[8] Pihlgren M(2015)Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios J Nucl Med 56 567-e1897

[9] Toni N(2018)ABBY: a phase 2 randomized trial of crenezumab in mild-to-moderate Alzheimer’s disease Neurology 90 e1889-198

[10] Varisco Y(1975)“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 189-1095